SAREUM HOLDINGS PLC (SAR) — Half Year Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SAREUM HOLDINGS PLC interim results investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged, and they can be submitted at any time using the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today and publish responses which is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to executive chairman, doctor Steven Parker. Good afternoon to you. Good afternoon, and good afternoon, everybody. Thank you for joining this call. I'm joined today by doctor John Reeder, our CSO, and doctor Tim Mitchell, our COO. We will each of us be taking part in the presentation and in answering your questions after that's finished. Just moving forwards, usual usual disclaimer with those with all of these presentations, we will be talking about future look forward looking events within this presentation and in the discussion, so please be aware of the disclaimer that goes with it. So a quick overview of where we are. You know about the company as being a clinical stage for a molecule drug company with deep expertise in kinase inhibitors, most notably, of course, in the TIC two JAK one field where we will spend most of the time today. But, happily, we're now back involved in the check one side having regained control of SRA seven three seven shortly after the period we're discussing ended. We are well funded now. We closed in the period with cash of 4,100,000 with a further 1,070,000 raised in early March. So t...